Tracleer (Bosentan) 62.5mg/125mg*30's | Endothelin Receptor Antagonist | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

分享
Product description

Generic Information: Tracleer (Switzerland)

Tracleer is the original brand of bosentan, developed and marketed by Actelion Pharmaceuticals, a Swiss company now part of Johnson & Johnson. This listing covers the 62.5 mg and 125 mg film-coated tablets, each supplied in a 30-tablet carton of hospital unit-dose blister strips, matching the two steps of the standard dosing schedule. Bosentan, first approved by the US FDA in 2001, was the world's first oral treatment for pulmonary arterial hypertension and remains a reference product in the endothelin receptor antagonist class.

What Is Tracleer Used For?

Tracleer treats pulmonary arterial hypertension (PAH), WHO functional class II to IV, in adults, improving exercise ability and reducing clinical worsening. It is also approved for children aged three years and older with idiopathic or congenital PAH. The condition is driven by elevated endothelin-1, a potent vasoconstrictor, and Tracleer counteracts this by blocking endothelin's effects on the lung's blood vessels.

How Does Bosentan Work?

Bosentan is a dual endothelin receptor antagonist that binds both the ETA and ETB receptors. By blocking endothelin-1 signaling, it relaxes constricted pulmonary blood vessels, lowers pulmonary vascular resistance, and eases the burden on the right ventricle of the heart. In the BREATHE-1 pivotal trial, bosentan produced a statistically significant improvement in six-minute walk distance and delayed the time to clinical worsening compared with placebo, establishing it as a foundational PAH therapy.

Indications

Tracleer is indicated for adults with pulmonary arterial hypertension (WHO Group 1) with functional class II to IV symptoms, and for pediatric patients three years and older with idiopathic or congenital PAH. The primary etiologies in the registration studies were idiopathic or heritable PAH, PAH associated with connective tissue disease, and PAH associated with congenital heart disease with left-to-right shunting.

Dosage

Adults begin with 62.5 mg twice daily for four weeks, then increase to 125 mg twice daily if tolerated. The tablets are taken morning and evening, with or without food. Because of the risk of liver toxicity and birth defects, liver enzymes are checked before treatment and monthly, and women of childbearing potential must use reliable contraception. Bosentan is dispensed only through a restricted program that requires prescriber, patient, and pharmacy enrollment.

Side Effects

The most common side effects are headache, flushing, fluid retention, and abnormal liver function tests. A dose-related reduction in hemoglobin can also occur, so blood counts are monitored during therapy. The serious risks are hepatotoxicity and embryo-fetal toxicity, which are managed through monthly liver monitoring and strict contraception. Patients should promptly report edema, weight gain, or new or worsening shortness of breath.

Storage

Store Tracleer at controlled room temperature, between 15°C and 30°C, in the original packaging, protected from moisture, and away from children. No cold-chain handling is required.

Why Choose the GLT?

GLT helps buyers source genuine, internationally approved medicines with verified supply chains and clear documentation. Tracleer is the originator bosentan, and while its list price in Western markets is high, we work with both institutions and individual patients to explain the pricing and regulatory differences across sourcing origins, so each buyer understands exactly what they are ordering and where it comes from.

How to Order

To order Tracleer through GLT, message us on WhatsApp at +86 15234153837 or write to [email protected]. Provide the strength, pack size, and delivery country, and our team will confirm availability, sourcing origin, and shipping terms. We work with hospitals, pharmacies, and individual patients.

FAQ

Who makes Tracleer? Tracleer is made by Actelion Pharmaceuticals, a Swiss company that is now part of Johnson & Johnson. Bosentan was originally approved by the FDA in 2001.

Is bosentan the same as Tracleer? Bosentan is the generic name, and Tracleer is the originator brand name. They refer to the same active ingredient.

Does bosentan require special monitoring? Yes. Because of the risks of liver toxicity and birth defects, patients require monthly liver function tests and women of childbearing potential must use reliable contraception.

Related Oncology Products

康曲欣 KangQuXin(阿伐曲泊帕)20mg×10片 | 北京康蒂尼(Gyre)| GLT

康曲欣 KangQuXin — 阿伐曲泊帕,北京康蒂尼药业(Gyre Therapeutics,纳斯达克:GYRE)出品,中国大陆

AVATODX(阿伐曲泊帕)20mg*30片 | 大熊制药(老挝)| GLT

AVATODX——Bigbear Pharmaceutical (Lao) Co., Ltd. 生产的阿伐曲泊帕 20mg,老挝注册号 06L0985/23,30 片瓶装。

Zepbound(替尔泊肽)2.5–15mg/0.5mL 单剂量注射笔 | 礼来(美国)| GLT

Zepbound——礼来替尔泊肽单剂量注射笔,六种美国规格(2.5–15mg/0.5mL),用于慢性体重管理和阻塞性睡眠呼吸暂停。

Baricent(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Incepta Pharmaceuticals Ltd. | GLT

由 Incepta Pharmaceuticals Ltd.(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

KeZeRui 科瑞泽(阿伐曲泊帕)20mg*10片 | 四川科伦(中国)| GLT

KeZeRui——四川科伦药业的国采阿伐曲泊帕,中国一体化原料药+片剂制造商。

奥氟格列隆/奥格列龙(OriYo)0.8–17.2mg 片剂 | 孟加拉仿制药 口服 GLP-1 | GLT

孟加拉国民制药(National Drug Co.)仿制奥氟格列隆,6 剂量递增用于体重管理

奥氟格列隆/奥格列龙(LuciOrfor)0.8–17.2mg 片剂 | 老挝仿制药 口服 GLP-1 | GLT

卢修斯制药(老挝)有限公司出品奥氟格列隆(奥格列龙)仿制药,6 档剂量递增方案,用于体重管理

SPINRAZA(诺西那生钠)12mg/5mL | 中国购买 | SMA 疗法 | GLT

渤健首创的反义寡核苷酸 SMA 疗法,已获 NMPA 批准并纳入中国国家医保——从 GLT 购买,价格仅为欧美的一小部分。